natgillin/translations-raw huggingface dataset:
If well tolerated (see section 4.4), the rate of administration may gradually be increased to a maximum of 4.8 ml/kg bw/hr. 
U slučaju dobrog podnošenja (vidjeti dio 4.4), primijenjena doza postupno se može povećati na najviše 4,8 ml/kg TT/sat.
Patients must be closely monitored and carefully observed for any symptoms throughout the infusion period. 
- budu pažljivo nadzirani u svrhu uočavanja eventualnih simptoma tijekom razdoblja primjene infuzije.
1 ml contains: Human normal immunoglobulin 100 mg. IgG purity ≥ 98%. 
1 ml sadrži: Ljudski normalni imunoglobulin 100 mg
In case of renal impairment, IVIg discontinuation should be considered. 
U slučaju oštećenja bubrežne funkcije treba razmotriti prekid i.v.Ig terapije.
Monitor patients for pulmonary adverse reactions. 
Bolesnike pratiti u slučaju plućnih nuspojava.
No differences were seen in the pharmacodynamic properties between adult and paediatric study patients. 
Nisu uočene razlike u farmakodinamičkim svojstvima između odraslih osoba i djece u ispitivanjima.
In patients at risk of acute renal failure, IVIg products should be administered at the minimum rate of infusion and dose practicable. 
U bolesnika pod rizikom za akutno zatajenje bubrega i.v.Ig lijekove treba primijeniti minimalnom provedivom brzinom infuzije i dozom.
- Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of <4 g/l. 
- Sekundarne imunodeficijencije (SID) u bolesnika s teškim ili rekurentnim infekcijama, onih u kojih antimikrobno liječenje nije bilo učinkovito te s dokazanim nedostatkom stvaranja specifičnog antitijela (PSAF)* ili s koncentracijom IgG-a u serumu <4 g/l. * PSAF = (engl. proven specific antibody failure) = nemogućnost postići barem dvostruki porast titra IgG antitijela na polisaharidne i polipeptidne antigene u pneumkoknim cjepivima.
Privigen is presented as a solution for infusion. 
Privigen je otopina za infuziju.
• transient decrease in red blood cells (reversible haemolytic anaemia/haemolysis), anaemia, leukopenia, anisocytosis (including microcytosis). 
• prolazni pad crvenih krvnih stanica (reverzibilna hemolitička anemija/hemoliza), anemija,
Other side effects presented in order of decreasing frequency: 
Druge nuspojave prikazane su prema opadajućoj učestalosti:
Blood tests Tell your doctor about your treatment with Privigen prior to having any blood tests. 
Prije obavljanja krvnih pretraga obavijestite svog liječnika o uzimanju Privigena.
• It is strongly recommended that every time you are given a dose of Privigen the name and batch number of the product are recorded in order to maintain a record of the batches used. 
• Preporučuje se bilježenje naziva i broja serije proizvoda pri svakoj primjeni Privigena kako bi se mogle pratili primijenjene serije lijeka.
Skin disorder (including rash, pruritus, urticaria, maculo-papular rash, erythema, skin exfoliation) 
urtikariju, makulopapularni osip, eritem, eksfolijaciju kože)
(e.g. you may feel light-headed, dizzy, faint on standing, cold in the hands and feet, sense an abnormal heart beat or chest pain, or have blurred vision) even when you have shown no hypersensitivity on previous infusions, Tell your doctor or healthcare professional immediately if you notice such signs during the infusion of Privigen. 
možete osjećati ošamućenost, omaglicu, nesvjesticu prilikom ustajanja, hladnoću u šakama ili stopalima, osjećaj abnormalnih srčanih otkucaja ili bolove u prsištu ili zamagljen vid) čak i ako niste imali preosjetljivost kod prethodnih infuzija,
The solution should be clear or slightly opalescent and colourless or pale yellow. 
Otopina treba biti bistra ili blago opalescentna te bezbojna ili blijedo žuta.
Tel: +386 1 25 71 496 
MediSanus d.o.o. Tel: +386 1 25 71 496
Pain (including back pain, pain in extremity, arthralgia, neck pain, facial pain) pyrexia (including chills), influenza like illness (including nasopharyngitis, pharyngolaryngeal pain, oropharyngeal blistering, throat tightness) 
(artralgija), bol u vratu, bol u licu), vrućica (uključujući zimicu), bolest nalik gripi (uključujući curenje nosa (nazofaringitis), grlobolju (faringolaringealna bol), mjehurići na sluznici usne šupljine i grla
200 or 400 ml of solution in a single vial (type II glass), with a stopper (elastomeric), a cap (aluminium crimp), a flip off disc (plastic), label with integrated hanger. 
200 ili 400 ml otopine u jednoj bočici (staklo tipa II), s čepom (elastomer), zaštitnim zatvaračem
- Chronic inflammatory demyelinating polyneuropathy (CIDP). 
- Kronične upalne demijelinizirajuće polineuropatije (KUDP).
Cases of acute renal failure have been reported in patients receiving IVIg therapy. 
U bolesnika koji primaju terapiju i.v.Ig-om zabilježeni su slučajevi akutnog zatajenja bubrega.
Dizziness (including vertigo) 
Omaglica (uključujući vrtoglavicu)
The pharmacokinetic parameters for Privigen were determined in a clinical study in PID patients (see section 5.1). 
Farmakokinetički parametri za Privigen utvrđeni su u kliničkom ispitivanju u
Aseptic technique must be strictly observed during the dilution of Privigen. 
Tijekom razrjeđivanja Privigena potrebno je strogo se pridržavati aseptičke tehnike.
EXP 
KUDP
The mean improvement at the end of the treatment period compared to reference visit was 1.4 points in the PRIMA (1.8 points in IVIg pretreated subjects) and 1.2 points in PATH study. 
PRIMA (1,8 bodova u ispitanika prethodno liječenih i.v.Ig-om) i 1,2 boda u PATH ispitivanju.
Patients with chronic inflammatory demyelinating polyneuropathy (CIDP). 
bolesnici s kroničnom upalnom demijelinizirajućom polineuropatijom.
The MRC responder rate, an increase of at least 3 points, was 84.8% which was similar in previously treated (81.5% [58.95, 100.00]) and untreated (86.7% [69.46, 100.00]) patients. 
Stopa bolesnika koji su odgovorili na liječenje prema MRC, odnosno porast od barem tri boda iznosio je 84,8% što je slično u prethodno liječenih (81,5% [58,95; 100,00]) i neliječenih bolesnika (86,7% [69,46; 100,00]).
Replacement therapy in primary immunodeficiency (PID) syndromes The dose regimen should achieve a trough IgG level (measured before the next infusion) of at least 5 to 6 g/l. 
Režimom doziranja se treba postići najniža IgG razina (izmjereno prije svake infuzije) od najmanje
Primary immune thrombocytopenia (ITP) 
Primarna imunotrombocitopenija (ITP)
If you get any side effects, talk to your doctor or healthcare professional. 
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika ili zdravstvenog radnika.
Thromboembolism 
Tromboembolije
Frequency of injections 
Učestalost ubrizgavanja
• acute renal failure, 
• akutno zatajenje bubrega,
• formation of blood clots which may be carried off in the blood circulation (thromboembolic reactions) and which may result e.g. in myocardial infarction (e.g. when you have sudden chest pain or shortness of breath), stroke (e.g. when you have a sudden onset of muscle weakness, have loss of sensation and/or balance, decreased alertness or difficulty in speaking), blood clots in the arteries of the lungs (e.g. when you have chest pain, difficulty in breathing or are coughing up blood), deep vein thrombosis (e.g. when you have redness, feel warmth, pain, tenderness, or have a swelling of one or both legs), 
• formiranje krvnih ugrušaka koji se mogu prenositi kroz cirkulaciju krvi (tromboembolijske reakcije) i mogu uzrokovati npr. srčani udar (primjerice, kada osjetite iznenadnu bol u prsištu ili nedostatak zraka), moždani udar (primjerice kada osjetite iznenadan nastanak mišićne slabosti,
0.4 g/kg bw/d for 5 days 
0,4 g/kg TT/dan tijekom 5 dana
2 g/kg bw every 4 to 8 weeks over 2 to 5 days 
preko 2 do 5 uzastopnih dana svaka 2 do 4 tjedna ili svakih 4 do 8 tjedana preko 2 do 5 dana
CSL Behring s.r.o. 
CSL Behring B.V.
0.4 g/kg bw/d for 2 to 5 days 
0,4 g/kg TT/dan tijekom 2 do 5 dana
25 ml of solution in a single vial (type I glass), with a stopper (elastomeric), a cap (aluminium crimp), a flip off disc (plastic), label with integrated hanger. 
25 ml otopine u jednoj bočici (staklo tipa I), s čepom (elastomer), zaštitnim zatvaračem (aluminij),
MedDRA System Organ Class (SOC) 
Klasifikacija organskih sustava prema MEDRA-i
In particular, patients naive to human normal immunoglobulin, patients switched from an alternative IVIg product or when there has been a long interval since the previous infusion should be monitored during the first infusion and for the first hour after the first infusion, in order to detect potential adverse signs. 
U ovim slučajevima bolesnike treba nadzirati tijekom primanja prve infuzije i jedan sat nakom primanja prve infuzije, a u svrhu otkrivanja mogućih nuspojava.
Affected are vaccinations with live attenuated virus vaccines such as vaccinations against measles, mumps, rubella and varicella. 
Umanjena je uglavnom djelotvornost živih atenuiranih virusnih cjepiva kao što su ona za ospice, zaušnjake, rubeolu i vodene kozice.
starting dose: 2 g/kg bw in divided doses over 2 to 5 days maintenance dose: 1 g/kg bw every 3 weeks over 1 to 2 days 
u podijeljenim dozama kroz 2 - 5 dana doza održavanja: 1 g/kg TT
Noncardiogenic pulmonary edema may very rarely occur following treatment with IVIg products, including Privigen. 
Prilikom liječenja s i.v.Ig lijekovima, uključujući Privigen, vrlo rijetko se pojavljuje nekardiogeni plućni edem.
starting dose: 0.4 - 0.8 g/kg bw maintenance dose: 0.2 - 0.8 g/kg bw every 3 to 4 weeks to obtain IgG trough levels of at least 5 - 6 g/l 
0,4 - 0,8 g/kg TT doza održavanja: 0,2 - 0,8 g/kg TT
In all patients, IVIg administration requires: - adequate hydration prior to the initiation of the infusion of IVIg - monitoring of urine output - monitoring of serum creatinine levels - avoidance of concomitant use of loop diuretics. 
- kontrolu diureze - praćenje razine kreatinina u serumu - izbjegavanje istodobne primjene diuretika Henleove petlje.
Vaccinations Tell your vaccinating doctor prior to a vaccination about your treatment with Privigen. 
Prije cijepljenja, obavijestite svog liječnika o svom liječenju Privigenom.
Tel: +385 1 631 1833 
PharmaSwiss d.o.o. Tel: +385 1 631 1833
Potential complications can often be avoided by ensuring that patients: - are not sensitive to human normal immunoglobulin by initially infusing the product slowly (0.3 ml/kg bw/hr); - are carefully monitored for any symptoms throughout the infusion period. 
- nisu osjetljivi na ljudski normalni imunoglobulin, polaganom infuzijom lijeka na početku primjene (0,3 ml/kg TT/sat);
For intravenous use only. 
Samo za primjenu u venu.
Reversible haemolytic reactions have been observed in patients, especially those with non-O blood groups in immunomodulatory treatment. 
Reverzibilne hemolitičke reakcije tijekom imunomodulatornog liječenja opažene su u bolesnika,
Pregnancy 
Cjepljenje
Secondary immunodeficiencies (as defined in 4.1) The recommended dose is 0.2 - 0.4 g/kg every three to four weeks. 
Preporučena doza je 0,2 - 0,4 g/kg svaka tri do četiri tjedna.
3 years 
godine.
Solutions that are cloudy or have deposits should not be used. 
Ne koristiti otopine koje su mutne ili sadrže talog.
The median doses administered for the 3-week and 4-week treatment schedules were almost identical to each other (428.3 vs. 440.6 mg IgG/ kg bw).The PID extension study included a total of 55 patients aged between 4 and 81 years old. 
Medijani doza primijenjenih prema 3-tjednom i 4-tjednom rasporedu bili su gotovo identični (428,3 naspram 440,6
The ability to drive and operate machines may be impaired by some adverse reactions associated with Privigen. 
Neke nuspojave povezane s lijekom Privigen mogu utjecati na sposobnost upravljanja vozilima i rada sa strojevima.
These include: careful selection of blood and plasma donors to make sure those at risk of carrying infections are excluded, the testing of each donation and pools of plasma for signs of virus/infections, the inclusion of steps in the processing of the blood or plasma that can inactivate or remove viruses. 
• uključivanje koraka u obradi krvi ili plazme koji mogu inaktivirati ili ukloniti viruse.
A total of 43 of the 207 patients achieved a better CIDP status as assessed by the adjusted INCAT score compared to their CIDP status at study entry. 
Ukupno 43 od 207 bolesnika postiglo je bolji status
Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally in connection with intravenous administration of human immunoglobulin including Privigen. 
Nuspojave kao što su zimica, glavobolja, omaglica, vrućica, povraćanje, alergijske reakcije, mučnina,
A vented infusion line should be used for the administration of Privigen. 
Za primjenu Privigena treba koristiti ventilirani sustav za infuziju.
In the second ITP study, 57 patients with ITP (baseline platelet counts ≤ 30×109 / l) aged between 18 
U drugom ITP ispitivanju 57 je bolesnika (broj trombocita na početku ispitivanja ≤30x109/1) u dobi između 18 i 65 godina liječeno Privigenom u dozi od 1 g/kg TT.
The recommended infusion rate given under section 4.2 must be closely followed. 
Nužno je pridržavati se preporučene brzine infuzije navedene u dijelu 4.2. Bolesnike se mora pomno pratiti i pažljivo nadzirati kako bi se uočili eventualni simptomi tijekom razdoblja primjene infuzije.
Tel: +420 702 137 233 
CSL Behring s.r.o. Tel: + 420 702 137 233
Human normal immunoglobulin 100 mg (purity of at least 98% IgG) 
Ljudski normalni imunoglobulin 100 mg
Aseptic meningitis syndrome (AMS) 
Sindrom primarrne imunodeficijencije (PID)
MediSanus d.o.o. 
AM Mangion Ltd.
Immunomodulation in adults, and children and adolescents (0-18 years) in: - Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count. 
Privigen se koristi za liječenje odraslih i djece (0-18 godina) u sljedećim situacijama: A) za povećanje nenormalno niskih razina imunoglobulina u Vašoj krvi na normalne razine
Breast-feeding 
KUDP-om.
Tel: +421 911 653 862 
CSL Behring s.r.o. Tel: +421 911 653 862
Adverse Drug Reaction 
FARMAKOLOŠKA SVOJSTVA
Human normal immunoglobulin 100 mg IgG purity ................................. ≥ 98% IgA ............................ ≤ 25 micrograms 
≥ 98% IgA…………………………..
Ask your doctor if you are not sure. 
Pitajte svog liječnika ako niste sigurni.
- if you have any blood disease. 
- ako bolujete od bilo koje bolesti krvi.
- if you are pregnant. 
- ako ste trudni.
Date of latest renewal: 26 August 2014 
Datum posljednje obnove: 26. kolovoza 2014.
DATE OF REVISION OF THE TEXT {MM/YYYY} 
DATUM REVIZIJE TEKSTA {MM/YYYY}
It will be the smallest quantity necessary to get the desired information. 
To će biti najmanja količina koja će omogućiti željene informacije.
69115 HEIDELBERG 
69115 HEIDELBERG NJEMAČKA
This medicinal product must not be mixed with other medicinal products except those mentioned in section 12. 
Lijek ne smije miješati s drugim lijekovima osim onih navedenih u dijelu 12.
- if you have had a scintigraphy with technetium in the last 2 days. 
- ako ste podvrgnuti scintigrafskoj pretrazi s tehnecijem u zadnja 2 dana.
This medicine is not recommended for use in patients below 18 years of age because the safety and efficacy of the product have not been established. 
Ovaj lijek se ne preporučuje za primjenu u bolesnika mlađih od 18 godina jer sigurnost i djelotvornost lijeka još nisu ustanovljene.
F-91192 Gif-sur-Yvette Cedex France 
F-91192 Gif-sur-Yvette Cedex Francuska
If you are pregnant you must not be given Scintimun. 
Ako ste trudni ne smijete primiti Scintimun.
MBq ml hour/date 
MBq ml sat/datum
Quality control 
Kontrola kvalitete
After radiolabelling: 3 hours. 
Nakon radioaktivnog obilježavanja: 3 sata.
DO NOT let the spot dry. 
NEMOJTE DOPUSTITI da se nanesena mrlja osuši.
Materials and reagents 
Materijali i reagensi
Scintimun will only be used in special controlled areas. 
Scintimun će se koristiti samo u posebno kontroliranom okruženju.
ATC code: V09HA03 
ATK oznaka: V09HA03
Specific warnings 
Specifična upozorenja
Withdrawals should be performed under aseptic conditions. 
Izvlačenje treba provesti u aseptičkim uvjetima.
There are strict laws on the use, handling and disposal of radiopharmaceutical products. 
Postoje strogi zakoni o upotrebi, rukovanju i odlaganju radiofarmaceutika.
Scintimun images should be interpreted in the context of other appropriate anatomical and/or functional imaging examinations. 
Slike je potrebno interpretirati u kontekstu odgovarajućih anatomskih i/ili funkcionalnih slikovnih prikaza.
Their receipt, storage, use, transfer and disposal are subject to the regulations and/or appropriate licences of the competent official organisation. 
Njihovo preuzimanje, čuvanje, primjena, prijenos i odlaganje podliježu propisima i/ili dozvolama nadležnih službenih tijela.
A single injection into a vein in your arm is sufficient to conduct the test your doctor needs. 
Dovoljna je jedna injekcija lijeka u venu na Vašoj ruci da se provede test potreban Vašem liječniku.
Trace a starting line 2.5 cm from the bottom of the paper strip. 
Označite početnu crtu 2,5 cm od dna papirnate trake.
The safety and efficacy of Scintimun in children and adolescents have not yet been established. 
Sigurnost i djelotvornost Scintimuna u djece i adolesenata nisu još ustanovljene.
Elderly No dose adjustment is required. 
Starije osobe Prilagodba doze nije potrebna.
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your nuclear medicine doctor for advice before you are given this medicine. 
Ako ste trudni ili dojite, mislite da biste mogli biti trudni ili planirate imati dijete, obratite se svom liječniku nuklearne medicine za savjet prije nego što Vam daju ovaj lijek.
Your doctor and the nuclear medicine doctor have considered that the clinical benefit that you will obtain from the procedure with the radiopharmaceutical outweights the risk due to radiation. 
Vaš liječnik i liječnik nuklearne medicine uzeli su u obzir da je klinička korist koju ćete dobiti od postupka s radiofarmaceutikom veća od rizika zbog zračenja.
Such substances should therefore not be administered together with, or a short time before the injection of Scintimun. 
Takve lijekove stoga ne treba primjenjivati zajedno s, ili kratko vrijeme prije injiciranja Scintimuna.
These persons will take special care for the safe use of this product and will keep you informed of their actions. 
Ove osobe će voditi posebnu brigu za sigurnu upotrebu ovog lijeka, te će vas obavijestiti o svojim postupcima.
Read all of this leaflet carefully before you are given this medicine because it contains important information for you. 
Pažljivo pročitajte cijelu uputu prije nego primite lijek jer sadrži Vama važne podatke.
The DHPC also includes 3 copies of a Patient Alert Card completed by the Healthcare Professional and provided to each patient. 
DHPC također sadrži 3 kopije Kartice s upozorenjima za bolesnika koju popunjavaju zdravstveni djelatnici i koju trebaju uručiti svakom bolesniku.
Tell your nuclear medicine doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription, since they may interfere with the interpretation of the images. 
Obavijestite svog liječnika nuklearne medicine ako uzimate nedavno ste uzeli ili biste mogli uzeti bilo koje druge lijekove, uključujući i one koje ste nabavili bez recepta jer mogu interferirati s tumačenjem slikovnih prikaza.
After radiolabelling with sodium pertechnetate ( 
PODACI KOJE MORA NAJMANJE SADRŽAVATI MALO UNUTARNJE PAKIRANJE Dodatna oznaka nakon rekonstitucije i radioaktivnog obilježavanja otopinom natrijevog pertehnetata (
The administration of radiopharmaceuticals creates risks for other persons from external radiation or contamination from spills of urine, vomiting, etc. 
Primjenom radiofarmaceutika nastaje rizik za druge ljude od vanjskog zračenja ili kontaminacije prolijevanjem urina, povraćanjem,itd..
The nuclear medicine doctor will inform you if you need to take any special precautions after receiving this medicine. 
Vaš liječnik nuklearne medicine će Vas obavijestiti ako je potrebno poduzeti bilo koje posebne mjere opreza nakon primitka ovog lijeka.
In case of allergic reaction you will receive appropriate treatment from your doctor. 
U slučaju alergijske reakcije liječnik će primijeniti odgovarajuće liječenje.
Acquisition can be performed using planar imaging. 
Snimanje može biti učinjeno planarnim prikazom.
After the procedure 
Nakon postupka
Radiopharmaceuticals should be prepared in a manner which satisfies both radiation safety and pharmaceutical quality requirements. 
Radiofarmaceutike treba pripremiti na način koji zadovoljava kako zahtjeve sigurnosti kod zračenja tako i farmaceutske zahtjeve kvalitete.
The other ingredients are (see section 2 “Scintimun contains sorbitol and sodium”): 
Ostali sastojci su (pogledajte dio 2 “Scintimun sadrži sorbitol i natrij“):
If you have an intolerance to some sugars (for example fructose or sorbitol), tell your doctor before you are given Scintimun. 
Ako ne podnosite neke vrste šećera (npr. fruktozu ili sorbitol), recite to svom liječniku prije nego primite Scintimun.
Pregnancy The use of besilesomab is contraindicated in pregnant women (see section 4.3). 
Primjena besilesomaba je kontraindicirana u trudnih žena (vidjeti dio 4.3).
Common (may affect up to 1 in 10 people): Low blood pressure 
Česte (mogu se pojaviti u do 1 na 10 osoba): Nizak krvni tlak
What Scintimun is and what it is used for What you need to know before you are given Scintimun How Scintimun is given 
Što je Scintimun i za što se koristi Što morate znati prije nego primite Scintimun Kako se daje Scintimun
To enable immediate action in emergencies, the necessary medicinal products and equipment such as endotracheal tube and ventilator must be immediately available. 
Kako bi se omogućilo trenutno djelovanje u hitnim slučajevima, potrebni lijekovi i medicinska oprema, kao što su endotrahealni tubus i ventilator moraju biti odmah dostupni.
This will protect your child from the radiation that may be present in your breast milk. 
Na taj način ćete zaštititi dijete od radioaktivnosti koja može biti prisutna u mlijeku.
The content of the kit before reconstitution is not radioactive. 
Sadržaj seta prije rekonstitucije nije radioaktivan.
If in doubt about her potential pregnancy (if the woman has missed a period, if the period is very irregular, etc.), alternative techniques not using ionising radiation (if there are any) should be offered to the patient. 
Ako ste u nedoumici oko njezine potencijalne trudnoće (ako je ženi izostala menstruacija, ako je menstruacija vrlo neredovita, itd), bolesnici treba ponuditi alternativne tehnike koje ne koriste ionizirajuće zračenje (ako postoje)
Pregnancy (see section 4.6). 
Trudnoća (vidjeti dio 4.6)
Do not store above 25 °C after radiolabelling. 
Ne čuvati iznad 25 °C nakon radioaktivnog obilježavanja.
Because you could emit radiation especially harmful to young children during the first 12 hours after the injection, you should avoid close contact with young children and pregnant women during this period of time. 
Zato što biste mogli emitirati zračenje posebno štetno za malu djecu tijekom prvih 12 sata nakon injekcije, trebate izbjegavati bliski kontakt s malom djecom i trudnicama tijekom tog vremenskog razdoblja.
Contact your nuclear medicine doctor if you have any questions. 
Obratite se svom liječniku nuklearne medicine ako imate bilo kakvih pitanja.
Scintimun contains sorbitol therefore patients with rare hereditary problems of fructose intolerance should not be administered this product. 
Scintimun sadrži sorbitol, stoga bolesnici koji imaju rijedak nasljedni poremećaj intolerancije fruktoze ne smiju primiti ovaj lijek.
This radiopharmaceutical will deliver low amounts of ionising radiation associated with the least risk of cancer and hereditary abnormalities. 
Ovaj radiofarmaceutik će isporučiti male količine ionizirajućeg zračenja povezanog s najmanjim rizikom od raka i nasljednih abnormalnosti.